Primary Outcome Measures:
Secondary Outcome Measures:
- Immunogenicity [ Time Frame: at Day 0, Day 21 and Day 180 ]
Effect of the initial clinical phenotype (including disease activity score) on the seroconversion and seroprotection rates, and the seroconversion factor, at each visit
- Clinical phenotype [ Time Frame: at Day 21 and Day 180 ]
Descriptive study of the evolution of clinical phenotype (eg, severity of illness) after vaccination at D21 and D180
- Auto immunity activity [ Time Frame: At Day 0, at Day 21 and at 6 months post-vaccination ]
Comparison of autoantibody levels before and after vaccination (anti-nuclear total, rheumatoid factor, anti-GM1 measured at D0, D21 and D180) in all individuals included in the study.
- Effect of therapy on immunogenicity [ Time Frame: at Day 21 and Day 180 ]
Effect of the dose of corticosteroids and immunosuppressive therapy on the seroconversion and seroprotection rates and seroconversion factor at D21 and D180;
- Immunogenicity between groups [ Time Frame: at Day 0, Day 21 and Day 180 ]
Comparison of the seroprotection rate and the seroconversion factor between patients with sarcoidosis and the control group of healthy subjects at D21 and D180 post-vaccination.
- Long term immune response [ Time Frame: At 6 months post-vaccination ]
Comparison of the persistence of the immune response between patients with sarcoidosis and control subjects at D180
- Lymphocytes subpopulations analysis [ Time Frame: At Day 0 and at 21 days post-vaccination ]
Comparison between D0 and D21 of the distributions in absolute values and percentages of circulating lymphocyte subpopulations, in particular mucosal "homing" CD4+ lymphocytes, in all individuals included in the study;
- Regulatory T Lymphocytes [ Time Frame: At Day 0 and Day 21 ]
Effect of the regulatory T cells titers on the seroconversion and seroprotection rates, and the seroconversion factor at D0
- Disease activity evolution [ Time Frame: at Day 0, Day 21 and Day 180 ]
Effect of the CD4+-CD103+ T cells + at J0 and its evolution between J0 and J21 days based on the scalability of sarcoidosis evaluated by 1/changes in serum enzyme angiotensin converting, IgG, IgA IgM,; 2/ the comparative pulmonary radiological changes and 3/ the in pulmonary function changes between day 0 and day 180.
- Other immune response [ Time Frame: Between Day 0 to 6 months post-vaccination ]
Seroprevalence and comparison between D0 and D180 of anti-diphtheria toxin and anti-tetanus toxin in all individuals included.
Data on vaccination in sarcoidosis are largely insufficient. It is thus unclear whether the vaccine response is modified according to the clinical phenotype of the disease and/or treatment with corticosteroids and immunosuppressants. However, sarcoidosis is accompanied by numerous disturbances of the immune system, including a tendency to anergy which may affect the efficacy of the vaccine, especially when the disease is active and severe. In addition, the tolerance of influenza vaccination in patients with sarcoidosis has not been studied yet.The influenza vaccination in sarcoidosis is a common practice among medical specialists who care for patients with sarcoidosis, either internists or lung specialists.. However, the practice of this vaccination is not based on scientific evidence, because there are no data establishing the efficacy and safety of influenza vaccination in sarcoidosis.Thus, it is possible that the influenza vaccine is less immunogenic in patients with sarcoidosis than in healthy adults, which may reduce the clinical effectiveness of vaccination. It therefore seems essential to determine the efficacy and safety of this vaccine, which is widely practiced. Poor efficiency could lead to the development of different vaccination strategies, based in particular on the administration of adjuvanted vaccines.